Pharmacodynamics and pharmacokinetics
The drug destroys the fibrin threads that are included in the main framework of the blood clot. The pattern of anti-inflammatory action is related to the effect on the oxidative function of tissue macrophages and blood neutrophils . The cardioprotective effect is associated with the normalization of blood supply to the myocardium .
The drug is low toxic. It does not reduce platelet and has no effect on clotting time or bleeding time.
The bioavailability of the drug is 20%. It is absorbed throughout the small intestine. The maximum concentration is reached after 5 hours.
The half-life is 12 minutes. If kidney function is impaired, it may increase. Up to 80% of the drug is excreted unchanged through the kidneys while maintaining specific activity. About 20% is broken down in the liver without causing toxic effects.
Release form and composition
Trombovazim is available in the following forms:
- tablets: white, with a yellowish-brown or light brown tint, unevenly colored, with elements of marbling, flat-cylindrical, with a score and a chamfer (10 pieces in contour strip packs, in a cardboard pack of 5, 7 or 10 packs);
- capsules: hard gelatin, size No. 0, with a white body and a dark pink cap, with a white inscription TROMBOVAZIM; contents – white powder with a yellowish-brown or light brown tint (4 pcs each in blister packs, 1 pack in a cardboard pack; 10 pcs in blister packs, 1, 3 or 5 packs in a cardboard pack);
- lyophilisate for preparing a solution for infusion: light yellow or light brown mass [in glass bottles with a capacity of 10 ml (dosage 200 IU, 400 IU and 600 IU) and 20 ml (dosage 1000 IU and 2000 IU); in a cardboard box 1, 2 or 3 bottles with a capacity of 10 ml or 1 or 2 bottles with a capacity of 20 ml].
Composition of 1 tablet:
- active ingredient: a complex of proteinase enzymes produced by Bacillus subtilis, adsorbed on macrogol 1500 with the addition of dextran by radiation - 200 IU;
- auxiliary components: sodium chloride, microcrystalline cellulose, potato starch.
Composition of 1 capsule:
- active ingredient: a complex of proteinase enzymes produced by Bacillus subtilis, adsorbed on macrogol 1500 with the addition of dextran by radiation - 400, 600 or 800 units;
- auxiliary components: sodium chloride, microcrystalline cellulose, potato starch;
- capsule shell: gelatin and dyes (titanium dioxide, patent blue V, azorubine).
1 bottle of lyophilisate contains a complex of proteinase enzymes produced by Bacillus subtilis, adsorbed on macrogol 1500 with the addition of dextran by radiation in the amount of 200, 400, 600, 1000 or 2000 units.
Contraindications
The medicine should not be used for:
- hypersensitivity to its components;
- breastfeeding;
- pregnancy;
- exacerbation of peptic ulcer of the stomach and duodenum ;
- childhood.
It is prescribed with caution in the case of polyvalent allergies , increased likelihood of bleeding from the veins of the esophagus, remission of gastric and duodenal ulcers , chronic obstructive pulmonary disease, urolithiasis .
Side effects
Possible side effects when taking Thrombovazim orally:
- digestive system: rarely - a feeling of heaviness in the stomach, nausea and vomiting;
- other reactions: possible - a feeling of fullness in the legs (temporary), allergic reactions.
Possible side effects with intravenous administration of Thrombovazim:
- cardiovascular system: decrease in blood pressure with rapid administration (drug discontinuation is not required, but it is recommended to reduce the rate of administration and use glucocorticosteroids in normal doses), reperfusion arrhythmias (the introduction of slow calcium channel blockers, insulin-glucose-potassium mixture helps reduce the risk of this syndrome and lidocaine);
- allergic reactions: chills, transient low-grade fever, etc. (it is recommended to use glucocorticosteroids);
- local reactions: pain and hyperemia along the vein, phlebitis.
Interaction
Heparin , acetylsalicylic acid and dipyridamole increase the antithrombotic effect without increasing the likelihood of bleeding. Combination with tetracycline antibiotics increases the effect of fibrinolytics . If you need to simultaneously take medications that contain divalent metal salts, this can lead to a decrease in enzyme , so it is recommended to take some time apart (at least 40 minutes).
Instructions for use
Thrombovazim is used to normalize venous circulation, improve the protection of vein walls, and prevent the formation of new blood clots in venous insufficiency. The drug has a triple mechanism of action:
- Dissolution of existing blood clots in the veins of the lower extremities;
- Normalization of microcirculation, restoration and increase in the speed of venous lymphatic flow, reduction of swelling of the lower extremities, reduction of pain;
- Anti-inflammatory effect, strengthening and restoring the integrity of vein walls, preventing the formation of new blood clots by stopping the polymerization of fibrin (a non-globular, high-molecular protein, the fibers of which are the main structural component of blood clots).
The drug Thrombovazim also promotes rapid healing of trophic ulcers.
When taking Thrombovazim, the instructions for the drug regulate the dosage and frequency of administration. As a rule, doctors prescribe standard dosages of the drug based on the clinical picture. Thus, the instructions define the maximum daily dose of Thrombovazim as 2000 units. There have been no cases of overdose with Trombovazim.
The recommended treatment regimen involves two doses of the drug Trombovazim per day, 1-2 capsules/tablets for 20 days. It is recommended to take the drug 30-40 minutes before meals.
If there is no expected effect from using Trombovazim, you should consult a doctor. At the beginning of the course of treatment with Thrombovazim, an exacerbation of varicose veins and chronic venous insufficiency is possible.
The main side effects of the drug Thrombovazim include:
- Allergic reactions;
- Dysfunction of the gastrointestinal tract (diarrhea, nausea, vomiting, feeling of heaviness in the stomach).
The drug Trombovazim does not affect a person’s ability to drive vehicles, as well as to perform work that requires increased attention and speed of physical and mental reaction, since its components are not substances that regulate the psychomotor state of a person.
The drug Trombovazim is safe due to its low toxicity. When taking Thrombovazim, it is necessary to take into account its interaction with drugs from other groups. Drugs such as heparin, acetylsalicylic acid, dipyridamole enhance the antithrombotic effect of Thrombovazim, while the risk of bleeding does not increase.
Tetracycline antibiotics (chlortetracycline hydrochloride, tetracycline, oxytetracycline hydrochloride) enhance the effect of fibrinolytics. If it is necessary to simultaneously use drugs of the tetracycline group and Thrombovazim, it is recommended to maintain a dosing interval of 30 to 40 minutes.
Analogs
Level 4 ATC code matches: Biostrepta
Actilyse
Gemaza
Fibrinolysin
Dystreptase
Streptokinase
Manufacturers claim that there are no analogues in the composition of Trombovazim. During its creation, advanced achievements of nuclear physics and the electron beam immobilization method were used. Biologically active substances are converted through radiation-activated polymer. The active component of the drug is represented by the proteinase , which is supplemented with an active polymer that protects it from the effects of the immune system.
Analogs of this drug by structural group do not differ in their complex action. However, Thrombovazim not only destroys blood clots , but also reduces the likelihood of new thrombus formations in the vessels of the lower extremities. This drug does not increase the risk of bleeding and has no serious side effects. It is approved for use in a wide group of patients.
Patient reviews, medical opinion
Thrombovazim is a safe drug for use, aimed at radically changing the clinical picture. Thrombovazim, reviews of which indicate a reduction in painful symptoms, swelling of the lower extremities, feelings of fatigue and heaviness in the legs, is positioned as an effective remedy for treating blood clots and preventing subsequent thrombus formation. However, Thrombovazim, reviews of which can be found on the Internet, according to doctors, is not such an effective means of eliminating blood clots. In traditional practice, to eliminate blood clots, drugs are administered intravenously or administered directly into the blood clot itself. It is extremely difficult to imagine the effectiveness of a thrombolytic in tablets.
Causes of varicose veins
Varicose veins are a fairly common pathology, mostly among the female half of the population. The disease occurs due to an increase in the diameter of the lumen of the veins and loss of elasticity of the walls of blood vessels. Previously, it was believed that overweight people were at risk, but today the disease can manifest itself in any person, regardless of body weight and age. A predisposing factor is weakness (congenital) of the venous walls. The main reasons for the development of varicose veins include:
- work involving prolonged sitting or standing;
- regularly wearing high-heeled shoes;
- tight clothes;
- doing strenuous sports (with a lot of stress on the legs);
- pregnancy (associated with an increase in blood volume in a woman’s body).
The treatment method will depend on the stage of the disease and clinical manifestations. Therefore, you should seek specialized help as soon as possible and not self-medicate. Untreated varicose veins over time lead to chronic venous insufficiency, which is fraught with the formation of blood clots.
Dosage
The daily dose should be selected strictly individually and only by the attending physician. The manufacturer recommends taking 800-1600 units (per day), dividing them into several doses. The dose can be either reduced or increased depending on the patient's condition. Only a specialist can control this.
The maximum daily dose is 2000 units; if it is exceeded, a side effect may occur. Reviews from patients indicate that such manifestations are rare. If there is no improvement in the condition after taking the drug, you should consult a doctor.
In what form is the medicine released?
This pharmaceutical product is available in the following form:
- Tablets are cylindrical in shape, with a color ranging from white to brownish with inclusions.
- Capsules, white-pink in color, with white or brownish powdery contents.
Both forms contain the active substance (enzyme) at 800, 600 and 400 units, respectively.
Doctors consider the highest dose acceptable for daily use to be 2000 units.
What dosage to choose in each specific case: Thrombovazim 800, 600 or 400 units - the attending physician will decide based on the results of tests and other diagnostic measures.
Drug trials
It is necessary about (reviews can be found on medical forums and websites) is a complete medicinal product, and not a food additive or dietary supplement. Having successfully passed preclinical and clinical trials, the domestic product has proven its effectiveness in the treatment of venous insufficiency, thrombosis, varicose veins, and myocardial infarction. The medicine is produced in a modern pharmaceutical factory equipped with the best equipment.
During preclinical studies, it was confirmed that the product (in the form of injections, capsules) is non-toxic and does not cause pathological changes in organs. Only after a positive result was the thrombolytic drug sent for clinical trials.
Breakthrough in the pharmaceutical industry
As you know, the formation of blood clots in blood vessels can lead to the most dire consequences. Thanks to the painstaking and long-term work of pharmacists in collaboration with nuclear physicists, it was possible to create a completely new medicine that can physically affect blood clots. The developers call it a “molecular surgeon”, since its effect extends exclusively to non-viable cells. The drug "Thrombovasim" is the first thrombolytic released in tablet form. This greatly simplifies treatment, since the patient can take the medicine without the help of medical personnel. "Thrombovasim" allows you to prevent dangerous diseases associated with the cardiovascular system (hemorrhagic and ischemic stroke, heart attack, venous insufficiency). Therefore, the developers advise using it as a prophylaxis to cleanse blood vessels from blood clots.
The drug was distinguished not only by its unique therapeutic effect, but also by the absence of negative consequences for the body. To create it, electron beam immobilization was used, which made it possible to reduce the toxic effect on the body as a whole. The drug is successfully used in complex therapy, promoting the transfer of molecules of other drugs that are difficult to penetrate through the intestinal walls on their own. Thus, the nanomedicine can enhance the therapeutic effect of other medications.
